This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Momenta Pharmaceuticals' Management Presents At Deutsche Bank BioFEST 2011 - Event Transcript

Stocks in this article: MNTA

Momenta Pharmaceuticals, Inc. (MNTA)

Deutsche Bank BioFEST

December 05, 2011 9:00 a.m. ET


Rick Shea - SVP and CFO

Ganesh Venkataraman - CSO, SVP, Research and Co-Founder


Robyn Karnauskas - Deutsche Bank Securities


Robyn Karnauskas - Deutsche Bank Securities

Thank you all for joining us and for those of you on the webcast. I am Robyn Karnauskas. And next, we have Momenta Pharmaceuticals. And it’s my pleasure to introduce, not only Rick Shea, the CFO, but also Ganesh Venkataraman – did I say that correctly – which is the one of the founders and chief scientific officer of Momenta.

And actually for those of you who are listening on the webcast, if you want to email me any questions, So with Ganesh here, he could answer any questions around their acquisition this morning and around some of the science behind Momenta.

And for those of you in the audience, again, we’re trying to use the DB app to sort of get some real-time feedback on the conference.

So with that, we’ll start off talking about – talking about Lovenox, first of all. You guys have been very successful with defending your patents. Maybe talk a little bit about -- you've got several cases actually ongoing. Maybe just give everyone in the audience an update on when is the next data point for each of those court cases? When we’re going to hear.

Rick Shea

So as you know we have been – in response to Amphastar’s approval for generic Lovenox on September 19, we sued Amphastar and Watson under our patents and obtained initially a temporary restraining order and then a temporary injunction against Amphastar and Watson, preventing them from launching.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs